Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:INGN NASDAQ:PROF NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.45-4.7%$9.23$6.55▼$10.49$47.98M-0.133,097 shs8,709 shsINGNInogen$6.21-1.6%$6.71$5.70▼$13.33$169.66M1.72169,161 shs444,994 shsPROFProfound Medical$5.50-0.9%$5.90$3.89▼$10.56$166.79M0.5232,498 shs19,816 shsTLSITriSalus Life Sciences$4.18-1.2%$5.07$3.50▼$6.04$160.06M0.539,551 shs60,247 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor-4.74%-6.80%-3.08%+25.50%+6.90%INGNInogen-1.58%-8.68%-16.31%-13.75%-32.86%PROFProfound Medical-0.90%-3.17%-9.69%+5.16%-48.02%TLSITriSalus Life Sciences-1.18%-8.33%-14.69%-18.20%-26.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen4.1998 of 5 stars3.33.00.03.92.91.71.3PROFProfound Medical1.8085 of 5 stars3.51.00.00.00.62.50.6TLSITriSalus Life Sciences2.1977 of 5 stars3.62.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00164.55% UpsideINGNInogen 2.50Moderate Buy$11.0077.13% UpsidePROFProfound Medical 3.00Buy$11.00100.00% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75157.18% UpsideCurrent Analyst Ratings BreakdownLatest DXR, TLSI, INGN, and PROF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/9/2025PROFProfound MedicalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy5/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AINGNInogen$335.70M0.50N/AN/A$7.30 per share0.85PROFProfound Medical$10.68M15.48N/AN/A$2.01 per share2.74TLSITriSalus Life Sciences$32.14M4.92N/AN/A($0.83) per share-5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AINGNInogen-$35.89M-$1.15N/AN/AN/A-8.08%-14.76%-9.01%8/7/2025 (Confirmed)PROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/6/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest DXR, TLSI, INGN, and PROF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43N/AN/AN/A$4.75 millionN/A8/13/2025Q2 2025TLSITriSalus Life Sciences-$0.22N/AN/AN/A$10.69 millionN/A8/7/2025Q2 2025INGNInogen-$0.25N/AN/AN/A$90.40 millionN/A5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/8/2025Q1 2025PROFProfound Medical-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AINGNInogenN/A3.072.67PROFProfound Medical0.0911.3110.03TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%INGNInogen89.94%PROFProfound Medical47.86%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%INGNInogen1.46%PROFProfound Medical1.52%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableINGNInogen1,03026.89 million26.49 millionOptionablePROFProfound Medical15030.05 million29.60 millionOptionableTLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableDXR, TLSI, INGN, and PROF HeadlinesRecent News About These CompaniesTriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 30 at 4:05 PM | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Stock Price Down 4.6% - Should You Sell?July 30 at 4:06 AM | marketbeat.comTriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallJuly 29, 2025 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24, 2025 | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendKinder Morgan: At the Hotspot of the Natural Gas RevolutionBy Thomas Hughes | July 21, 2025View Kinder Morgan: At the Hotspot of the Natural Gas RevolutionIs J.B. Hunt Stock a Sleeping Giant Heading Into 2026?By Thomas Hughes | July 19, 2025View Is J.B. Hunt Stock a Sleeping Giant Heading Into 2026?Retail’s Comeback: 3 High-ROIC Stocks That Could Outshine AIBy Gabriel Osorio-Mazilli | July 27, 2025View Retail’s Comeback: 3 High-ROIC Stocks That Could Outshine AIAbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025View AbbVie Stock Eyes Breakout as Pipeline and Profits GrowDXR, TLSI, INGN, and PROF Company DescriptionsDaxor NASDAQ:DXR$9.45 -0.47 (-4.74%) As of 08/1/2025 03:12 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Inogen NASDAQ:INGN$6.21 -0.10 (-1.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.22 +0.01 (+0.24%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Profound Medical NASDAQ:PROF$5.50 -0.05 (-0.90%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$5.52 +0.03 (+0.45%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.TriSalus Life Sciences NASDAQ:TLSI$4.18 -0.05 (-1.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.18 +0.00 (+0.12%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
